{
    "Clinical Trial ID": "NCT00373256",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sunitinib + Paclitaxel",
        "  Starting sunitinib doses of 25 mg daily. After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted.",
        "INTERVENTION 2: ",
        "  Bevacizumab + Paclitaxel",
        "  Bevacizumab 10 mg/kg; infusion duration according to standard of care. Paclitaxel starting dose of 90 mg/m^2, as a 1 hour infusion. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Diagnosis of advanced breast cancer.",
        "  Measurable disease as per RECIST (Response Evaluation Criterion) in Solid Tumors or bone-only disease.",
        "  ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1.",
        "Exclusion Criteria:",
        "  No prior treatment with cytotoxics in the advanced disease setting.",
        "  HER2/neu positive disease unless trastuzumab was previously received or is contraindicated.",
        "  Treatment with a taxane in the adjuvant setting unless disease free interval >12 months after end of treatment."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-Free Survival (PFS)",
        "  Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS = (first event date minus randomization date +1) divided by 30.4",
        "  Time frame: From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death",
        "Results 1: ",
        "  Arm/Group Title: Sunitinib + Paclitaxel",
        "  Arm/Group Description: Starting sunitinib doses of 25 mg daily. After Cycle 1, escalation to 37.5 mg daily was permitted in the absence of complicated neutropenia and if all 3 Cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at discretion of the investigator. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted.",
        "  Overall Number of Participants Analyzed: 242",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  7.4        (6.9 to 8.5)",
        "Results 2: ",
        "  Arm/Group Title: Bevacizumab + Paclitaxel",
        "  Arm/Group Description: Bevacizumab 10 mg/kg; infusion duration according to standard of care. Paclitaxel starting dose of 90 mg/m^2, as a 1 hour infusion. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerability; re-escalation to 80 or 90 mg/m^2 upon recovery was permitted.",
        "  Overall Number of Participants Analyzed: 243",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  9.2        (7.7 to 13.0)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 89/235 (37.87%)",
        "  Anaemia 3/235 (1.28%)",
        "  Febrile neutropenia 12/235 (5.11%)",
        "  Leukopenia 1/235 (0.43%)",
        "  Neutropenia 6/235 (2.55%)",
        "  Pancytopenia 2/235 (0.85%)",
        "  Thrombocytopenia 2/235 (0.85%)",
        "  Atrial fibrillation 1/235 (0.43%)",
        "  Cardiac failure congestive 1/235 (0.43%)",
        "  Cardiogenic shock 1/235 (0.43%)",
        "  Cardiovascular disorder 0/235 (0.00%)",
        "Adverse Events 2:",
        "  Total: 85/242 (35.12%)",
        "  Anaemia 1/242 (0.41%)",
        "  Febrile neutropenia 3/242 (1.24%)",
        "  Leukopenia 0/242 (0.00%)",
        "  Neutropenia 2/242 (0.83%)",
        "  Pancytopenia 0/242 (0.00%)",
        "  Thrombocytopenia 0/242 (0.00%)",
        "  Atrial fibrillation 2/242 (0.83%)",
        "  Cardiac failure congestive 1/242 (0.41%)",
        "  Cardiogenic shock 0/242 (0.00%)",
        "  Cardiovascular disorder 1/242 (0.41%)"
    ]
}